Prem S Pais
Impact in
-
- Blood Pressure and Hypertension Studies
- Cardiac Health and Mental Health
- Atrial Fibrillation Management and Outcomes
- Acute Myocardial Infarction Research
-
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
Papers in
-
- Medication Adherence and Compliance 11
-
- Blood Pressure and Hypertension Studies 10
- Heart Failure Treatment and Management 4
- Co-authors
- Salim Yusuf (38 shared papers)Álvaro Avezum (5 shared papers)Andrzej Budaj (6 shared papers)George Varigos (1 shared paper)Matthew McQueen (1 shared paper)Steven Hawken (1 shared paper)Stephanie Ôunpuu (1 shared paper)Fernando Tomas Lanas (1 shared paper)
- Journals
- The Lancet (10 papers)American Heart Journal (8 papers)Circulation (5 papers)New England Journal of Medicine (5 papers)European Heart Journal (3 papers)
- Partner nations
- CanadaIndiaUnited States
In The Last Decade
Prem S Pais
86 papers receiving 23.2k citations
Prem S Pais's Hit Papers
Peers
Comparison fields: 5 of 179
- Cardiology and Cardiovascular Medicine 8.2k
- Endocrinology, Diabetes and Metabolism 5.4k
- Family Practice 477
- Internal Medicine 549
- Epidemiology 3.1k
Countries citing papers authored by Prem S Pais
This map shows the geographic impact of Prem S Pais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prem S Pais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prem S Pais more than expected).
Fields of papers citing papers by Prem S Pais
This network shows the impact of papers produced by Prem S Pais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prem S Pais. The network helps show where Prem S Pais may publish in the future.
Co-authors
The 25 scholars most cited alongside Prem S Pais, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 86 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Hit paper breakdown → | 2004 | 9155 |
| 2 | Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study Hit paper breakdown → | 2010 | 2619 |
| 3 | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2019 | 2307 |
| 4 | Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study Hit paper breakdown → | 2016 | 1635 |
| 5 | Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Hit paper breakdown → | 2010 | 811 |
| 6 | Risk Factors for Early Myocardial Infarction in South Asians Compared With Individuals in Other Countries Hit paper breakdown → | 2007 | 795 |
| 7 | Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease Hit paper breakdown → | 2016 | 683 |
| 8 | Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events Hit paper breakdown → | 2008 | 614 |
| 9 | Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data Hit paper breakdown → | 2008 | 496 |
| 10 | Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hit paper breakdown → | 2019 | 492 |
| 11 | Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease Hit paper breakdown → | 2016 | 470 |
| 12 | 2014 | 298 | |
| 13 | Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease Hit paper breakdown → | 2016 | 297 |
| 14 | 2008 | 284 | |
| 15 | 2018 | 278 | |
| 16 | 2013 | 269 | |
| 17 | 1996 | 255 | |
| 18 | Polypill with or without Aspirin in Persons without Cardiovascular Disease Hit paper breakdown → | 2020 | 194 |
| 19 | 2009 | 176 | |
| 20 | 2010 | 148 |
About Prem S Pais
Prem S Pais is a scholar working on Family Practice, Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Geriatrics and Gerontology and Epidemiology, having authored 86 papers that have together received 24.6k indexed citations. Recurring topics across this work include Medication Adherence and Compliance (11 papers), Blood Pressure and Hypertension Studies (10 papers), Lipoproteins and Cardiovascular Health (8 papers), Acute Ischemic Stroke Management (7 papers), Diabetes Treatment and Management (6 papers), Global Public Health Policies and Epidemiology (5 papers), Pharmaceutical Practices and Patient Outcomes (5 papers) and Heart Failure Treatment and Management (4 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (8.2k citations), Endocrinology, Diabetes and Metabolism (5.4k citations), Family Practice (477 citations), Internal Medicine (549 citations) and Epidemiology (3.1k citations). Prem S Pais has collaborated with scholars based in Canada, India and United States. Frequent co-authors include Salim Yusuf, Álvaro Avezum, Andrzej Budaj, George Varigos, Matthew McQueen, Steven Hawken, Stephanie Ôunpuu, Fernando Tomas Lanas, Denis Xavier and Khawar Abbas Kazmi. Their work appears in journals such as The Lancet, American Heart Journal, Circulation, New England Journal of Medicine and European Heart Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.